Mylan CEO Heather Bresch said Wednesday the company is developing an EpiPen formulation that would extend the shelf life of the product, according to Bloomberg.
The comments were made during her hearing with the House Oversight Committee.
At present, EpiPens have a shelf life of 18 months. The new formulation would boost time between refills to two years.
Ms. Bresch said Canonsburg, Pa.-based Mylan has been working on the reformulation for two years and hopes to submit it to the Food and Drug Administration within days.
More articles on supply chain:
Mylan CEO defends price hikes during heated EpiPen hearing: 5 takeaways
Self-directed robots are the new warehouse workers
Athenahealth CEO: EpiPen price hikes shouldn't be a political issue